The online-only Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/Background-Prolonged P-wave duration, indicating atrial conduction delay, is a potent precursor of atrial fibrillation.
O bstructive sleep apnea (OSA) is recognized as a potent risk factor for the development of atrial fibrillation (AF), 1, 2 and this may be because of its pathophysiological effects, including mechanical and autonomic cardiovascular effects, activation of systemic inflammation, and production of reactive oxygen species. [3] [4] [5] [6] [7] [8] [9] These pathophysiological effects of OSA may cause left atrial overload and remodeling, and consequently, atrial conduction disturbances that contribute to AF.
Clinical Perspective on p 293
P-Wave duration is a simple index of atrial conduction time. 10 Indeed, several studies including ours have shown a relationship between the presence or severity of OSA and the P-wave prolongation on a standard 12-lead ECG. 11 However, compared with P-wave duration on a standard 12-lead ECG, P-wave duration that is assessed with a signal-averaged ECG (signal-averaged P-wave duration [SAPWD]) has been established as a more reliable and accurate index of global atrial conduction. 10, 12 In addition, SAPWD has been shown to be a predictor of the development of AF. 10, [12] [13] [14] [15] [16] [17] To date, however, no studies have investigated the relationship between OSA and P-wave duration using signal-averaged ECG. In addition, none of the previous studies that examined the relationship between OSA and P-wave duration on standard 12-lead ECG showed causality. Therefore, we conducted this study: (1) to assess whether there was a dose-response relationship between the severity of OSA and atrial conduction as assessed by a reliable technique (ie, SAPWD), and (2) to investigate whether effective OSA suppression by continuous positive airway pressure (CPAP) affected SAPWD to determine the relationship between OSA and atrial conduction disturbance.
Methods
For a more detailed description of the methods, please see the onlineonly Data Supplement.
Participants
Eighty consecutive male participants who underwent overnight attended polysomnography in the Sleep Center of the Toranomon Hospital (Tokyo, Japan) from January to October 2010 were enrolled in the study if the following criteria were met: (1) age ≥20 years and (2) normal sinus rhythm on a standard 12-lead ECG, in which every P-wave was positive in leads I, II, and aVF with uniform morphologies, every QRS complex was preceded by a P-wave, and every P-wave was followed by a QRS complex. Participants were excluded if they had any of the following: (1) a history of AF/flutter or treatment with sodium channel blockers, β-blockers, diltiazem, and/ or verapamil; (2) a pacemaker or implantable cardioverter defibrillator; (3) evidence of heart failure; (4) a history of ischemic heart disease; (5) significant valvular heart disease; (6) severe chronic pulmonary disease; (7) a need for dialysis; or (8) predominant central sleep apnea.
The apnea-hypopnea index (AHI) was used to evaluate OSA severity. AHI, which was calculated as the total number of apnea and hypopnea events divided by the total sleep time, was expressed as the number of events per hour. Participants were divided into the following categories according to the AHI: no or mild OSA (AHI<15 events/h), moderate OSA (15≤AHI<30 events/h), and severe OSA (AHI≥30 events/h).
Venous blood samples were obtained early in the morning after overnight fasting and immediately after the sleep study. Blood pressure (BP), heart rate (HR), height, and weight were measured just before the signal-averaged ECG was conducted.
The Toranomon Hospital Ethics Committee approved the study, and written informed consent for participation was obtained from all participants.
Signal-Averaged ECG and Measurement of P-Wave Duration
A P-wave signal-averaged ECG was performed on the same day as the sleep study in an electrically shielded room after the patient rested in a supine position for at least 15 minutes. The P-wave signalaveraged ECG was recorded from a modified X, Y, and Z lead system with FCP-7541 (Fukuda Denshi Co, Ltd, Tokyo, Japan). Signals from each lead were amplified and filtered using a low-pass filter of 300 Hz (slope, 12 dB/oct) and a high-pass filter of 40 Hz (slope, 18 dB/oct). The signals were averaged on a trigger point of the P-wave after supraventricular and ventricular ectopic beats were eliminated through template-matching programs. The P-waves were acquired until a mean noise level ≤0.4 μV was achieved.
The P-wave complexes from the X, Y, and Z leads were combined into a vector magnitude using the formula (X 2 +Y 2 +Z 2 ) 1/2 . The P-wave duration was defined as the interval between the onset and the offset point in the vector magnitude where the voltage showed a persistent level of >0.4 μV. The measurement of the P-wave duration was conducted manually with the FCP-7541 and accompanying software in a random fashion by an experienced observer who was blinded to the participants' information and polysomnographic data. To determine the reproducibility of SAPWD, coefficients of variation (CV) were obtained from measurements repeated 3 different times in 10 randomly selected patients. The average coefficients of variation was 1.1%.
CPAP Therapy and Follow-up
Among the participants, all patients who were diagnosed with moderate-to-severe OSA (AHI≥15 events/h) were counseled and treated with CPAP therapy after manual ascertainment of the effectiveness and appropriate pressure setting in a second (CPAP titration) study. After 1 month of CPAP treatment, a signal-averaged ECG was repeated along with measurements of BP, HR, and weight. An objective evaluation of adherence was conducted by downloading the data stored in the CPAP device. Furthermore, as controls, 18 consecutive patients with moderateto-severe OSA were separately enrolled using the same inclusion and exclusion criteria. In this control group, a signal-averaged ECG was repeated along with measurements of BP, HR, and weight 1 month after the baseline sleep study without any therapy for OSA.
Statistical Analysis
The data are expressed as the mean±SD for normally distributed continuous variables, as medians (25th-75th percentile) for non-normally distributed continuous variables, or as numbers and percentages for categorical variables. Because the AHI and high-sensitivity C-reactive protein concentrations were skewed, the natural log-transformed AHI and high-sensitivity C-reactive protein levels were used for all statistical analyses. Correlations between SAPWD and clinical parameters were analyzed with Pearson correlation coefficients. To identify factors that were independently correlated with SAPWD, we conducted multivariable regression analysis that included SAPWD as a dependent variable and variables that were regarded as significant (ie, P<0.1) in the univariable analyses as independent variables. Collinearity was verified between each pair of variables. Furthermore, to consider the confounding effect of BSA on the relationship between log-transformed AHI and SAPWD, an additional regression analysis with the ratio of SAPWD/BSA as the dependent variable was conducted with the same independent variables excluding either body mass index (BMI) or BSA. The baseline characteristics of patients treated with CPAP and controls were compared using an unpaired Student t test for continuous variables and the χ 2 test for categorical variables. Paired and unpaired Student t tests were used to assess changes after 1 month within a group and between groups, respectively. Correlations between changes in SAPWD over 1 month and changes in BMI, systolic BP, diastolic BP, HR, device adherence, and baseline log-transformed AHI were also assessed in patients who underwent CPAP treatment. P values <0.05 were considered statistically significant. Statistical analyses were performed using StatView (version 5.0; SAS Institute, Inc, Cary, NC).
Results

Characteristics of Participants
The characteristics of all participants are shown in Table 1 . The participants were generally middle-aged. Of them, 53% had hypertension, 10% had diabetes mellitus, 44% had dyslipidemia, 20% were current smokers, and 31% had a habit of heavy alcohol drinking.
The sleep study data are summarized in Table 2 . Among the 80 participants, 18 (23%) had no or mild OSA, 22 (28%) had moderate OSA, and 40 (50%) had severe OSA.
Factors Related to SAPWD
In the univariable analyses, age (r=0.42; P<0.001), BMI (r=0.32; P=0.004), BSA (r=0.21; P=0.068), hypertension (r=0.41; P<0.001), estimated glomerular filtration rate (r=−0.24; P=0.029), log-high-sensitivity C-reactive protein (r=0.38; P<0.001), and HR (r=0.20; P=0.077) showed significant relationships with SAPWD. In addition, the logtransformed AHI showed a significant positive correlation with SAPWD (r=0.71; P<0.001; Figure 1 ). Multivariable regression analysis, which included SAPWD as the dependent variable and age, BMI, hypertension, estimated glomerular filtration rate, log-high-sensitivity C-reactive protein, HR, and log-transformed AHI as independent variables, identified age (partial correlation coefficient, 0.25; P=0.035), hypertension (partial correlation coefficient, 0.27; P=0.025), and log-transformed AHI (partial correlation coefficient, 0.56; P<0.001) as significant independent correlates of SAPWD. Additional multivariable regression analysis using BSA instead of BMI along with other independent variables identified age, hypertension, and log-transformed AHI as significant independent correlates of SAPWD (Table 3) .
Moreover, we assessed the factors related to the SAPWD/ BSA ratio. In univariable analyses, age (r=0.55; P<0.001), hypertension (r=0.27; P=0.017), Epworth sleepiness scale (r=−0.23; P=0.041), and log-transformed AHI (r=0.34; P=0.002) showed significant associations with SAPWD/BSA. Multivariable regression analysis identified age and log-transformed AHI as significant independent correlates of SAPWD/ BSA (Table 4 ).
Change in SAPWD After 1 Month of CPAP Therapy
In 62 patients with moderate-to-severe OSA, CPAP was titrated for all patients and was shown to significantly reduce AHI (from 36.5 [25.7-50.2] to 1.6 [0.8-2.7] events/h; P<0.001 in the analysis after log-transformation). All these patients accepted CPAP therapy and completed the 1-month study. The average hours of CPAP usage were 4.6±1.3 h/night during this month.
Baseline characteristics of the control group and the 62 patients who underwent CPAP are shown in Table 5 . No significant differences were found between the two groups, including in SAPWD at baseline. There were no new reported cardiovascular diseases or medication changes during the 1-month period in either group.
There were no significant changes in BMI, systolic BP, diastolic BP, HR, or SAPWD (Figure 2 ) between baseline and 1 month in the control group. In patients treated with CPAP, no significant changes were identified in BMI, systolic BP, or diastolic BP, whereas HR significantly decreased after 1 month (from 72.9±10.5 to 69.7±10.1 beats per minute; P=0.007). The SAPWD values in these patients were significantly reduced ( Figure 2 ). The change in SAPWD in patients receiving CPAP was significantly greater than that in controls ( Figure 2 ). In patients treated with CPAP, the change in SAPWD was inversely correlated with nightly CPAP usage (r=−0.52; P<0.001) and logtransformed AHI (r=−0.31; P=0.016), whereas the change Data are expressed as the mean±SD or as number (percentage), except for hsCRP, which is expressed as median (25th-75th percentile). BMI indicates body mass index; eGFR, estimated glomerular filtration rate; hsCRP, highsensitivity C-reactive protein; LVH, left ventricular hypertrophy; and SAPWD, signal-averaged P-wave duration. in SAPWD did not correlate with changes in BMI, systolic BP, diastolic BP, or HR.
Table 2. Sleep Study Findings
Discussion
The present study elucidated several important findings, which provide insight into the possible relationship between atrial arrhythmias and OSA. The log-transformed AHI was independently related to SAPWD in a dose-response manner. The SAPWD values significantly decreased after 1 month of CPAP therapy for OSA, whereas no significant change in SAPWD was found between the baseline and the 1-month examination in controls. To the best of our knowledge, this is the first study to show an independent dose-response relationship between the severity of OSA and prolonged SAPWD and a shortening of SAPWD after 1 month of OSA treatment with CPAP. These findings suggest that there is a cause and effect relationship between OSA and prolonged SAPWD. This was further supported by the observed correlation between nightly CPAP usage and SAPWD.
Delayed atrial conduction contributes to the onset and maintenance of AF by stabilizing AF-sustaining reentry circuits. 18 A high correlation between atrial conduction time and P-wave duration during sinus rhythm has been demonstrated. 10, 19 SAPWD is thought to be a reliable noninvasive surrogate measure of atrial activation time. 10, 12 Electrophysiological evaluations have revealed that SAPWD is significantly and positively correlated with conduction time in the left atrium. 20 In contrast, SAPWD has been demonstrated to be significantly correlated with left atrial pressure and left atrial size. 14, 21 There are no reports to specifically investigate the relationship between SAPWD and changes in electrophysiology, pressure, or size of the right atrium. However, changes in electrophysiology, pressure, or size of the right atrium might affect the SAPWD in addition to such changes of the left atrium. Atrial pressure overload and subsequent atrial stretch and atrial dilatation play an important role in the development of the substrate for AF during sinus rhythm. 12, 18, 22 Thus, SAPWD is thought to represent global atrial conduction, including the influences of underlying electric and/or structural remodeling, in the assessment of atrial conduction properties, and its prolongation could become a potent precursor of AF. In fact, SAPWD has been demonstrated to be significantly longer in patients with a history of AF than in those without a history of AF, and prolonged SAPWD is a predictor of AF development in patients with systolic heart failure, acute myocardial infarction, and after cardiac surgery. [13] [14] [15] [16] [17] Prolonged SAPWD, therefore, has been considered an accurate marker of risk for development of AF. 10, 12 Several potential pathophysiological conditions may directly and indirectly predispose patients with OSA to the development of prolonged SAPWD. As an indirect mechanism, left ventricular diastolic dysfunction, which frequently occurs in patients with OSA, 3 can result in elevated left atrial pressure, increased left atrial dimension, 4 and consequently, prolonged SAPWD. As a direct mechanism, Orban et al 5 reported that swings in intrathoracic pressure by the Mueller maneuver, which simulates OSA, could cause an increase in left atrial stretch. However, the exaggerated negative intrathoracic pressure by OSA might also cause an increase in right atrial stretch through the increased venous return. In addition to increased atrial stretch, atrial fibrosis, which is an important contributor to atrial conduction disturbance, can also be promoted by mechanical stretch through cardiomyocytefibroblast crosstalk. 22 Activated inflammatory responses and increased oxidative stress that are related to OSA 7-9 can facilitate such atrial fibrosis. 23 In addition, increases in the serum levels and activity of matrix metalloproteinase-9 in patients with OSA may also play some roles in this atrial fibrosis. 24, 25 This idea is supported by a recent study of electrophysiological findings in patients with paroxysmal AF. 26 In this study, during sinus rhythm, a slower regional conduction velocity was observed in the various regions of the right and left atria in patients with coexisting OSA. Data are expressed as the mean±SD or as number (percentage) as appropriate, other than hsCRP and AHI, which are expressed as median (25th-75th percentile). Statistical analyses were performed using log-hsCRP and logtransformed AHI values. AHI indicates apnea-hypopnea index; BMI, body mass index; CPAP, continuous positive airway pressure; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; LVH, left ventricular hypertrophy; and SAPWD, signal-averaged P-wave duration.
Furthermore, a greater number of fractionated electrograms were widely distributed in both atria. These observations strongly suggest the presence of atrial fibrosis because interstitial fibrosis forces activation to follow a tortuous route between the electric barriers and interferes with local conduction. 18, 22 In addition, the mixture of myocardial and fibrotic bundles results in asynchronous conduction, which typically generates fractionated electrograms. 27 The significant shortening of SAPWD after 1 month of CPAP therapy that was observed in the present study may be proof of a cause and effect relationship between OSA and atrial conduction disturbances that were expressed as prolonged P-wave durations. In other words, our finding suggests that atrial conduction disturbances, which reflect AF pathogenesis, may be a modifiable target in patients with moderateto-severe OSA because the pathophysiological effects of OSA, including the mechanical and autonomic effects, can also be alleviated by CPAP therapy. 28, 29 In addition, several studies have shown reductions in the levels of inflammation markers, oxidative stress markers, and matrix metalloproteinase-9 by CPAP therapy for OSA, [7] [8] [9] 24 suggesting that CPAP therapy for OSA may blunt the progression of atrial fibrosis. Furthermore, several studies have shown a significant improvement in left ventricular diastolic function after initiation of CPAP therapy for OSA. 3 However, most studies that have used echocardiograms have failed to show a reduction in the left atrial dimension after CPAP therapy for OSA. 3, 30 One possible reason for these negative results on a reduction in atrial dimension by CPAP therapy is that improvements in atrial size may require a longer time course than alleviation of the pathophysiological effects of OSA and improvements in diastolic dysfunction. In addition, the degree of existing irreversible structural changes before CPAP initiation may also affect such negative results. In terms of atrial pressure overload and SAPWD, Faggiano et al 21 reported a reduction in left atrial pressure with short-term infusion of sodium nitroprusside, which resulted in a parallel reduction in SAPWD. On the basis of these observations, the changes in SAPWD after 1 month of CPAP therapy in the present study may be attributable more to the lowering of left atrial pressure overload rather than to structural changes in the left atrium.
Although OSA has been demonstrated to be a risk factor for the development of AF, 1,2 our study suggests the possibility of improving the substrate for AF after short-term application of CPAP for OSA. An observational study showed that the number of recurrences of AF 1 year after successful cardioversion was significantly lower in OSA patients treated with CPAP than in those not treated with CPAP. 31 These observations lead to the hypothesis that the long-term application of CPAP is an upstream therapy for preventing AF in patients with OSA. Nevertheless, we did not obtain long-term follow-up data for SAPWD after CPAP therapy in the present study. Therefore, the effects of CPAP on the incidence of atrial arrhythmias by preventing prolonged SAPWD are unknown.
Study Limitations
The present study has several limitations. The first was the relatively small number of participants, all of whom were men. We focused on men because the prevalence of moderate-to-severe OSA in women is generally low, 32 and indeed, we could not find any eligible women during the period of the present study. In addition, although men with paroxysmal AF have prolonged SAPWD, SAPWD in women with paroxysmal AF is less prolonged, and the sensitivity of SAPWD to detect the presence of paroxysmal AF in women is low compared with men, even with the use of sex-specific values. 33 These observations suggest that the relationship between SAPWD and OSA may be less pronounced in women. Therefore, the results of the present study may not be applicable to women. Second, the effects of CPAP therapy on SAPWD were not assessed with a randomized controlled design. However, we found significant correlations between nightly CPAP usage and the reduction in SAPWD. Third, Figure 2 . Individual changes in signal-averaged P-wave duration (SAPWD) for 1 month. No significant changes were observed in SAPWD during 1 month in the control group, whereas in the continuous positive airway pressure (CPAP) group, SAPWD was significantly reduced. In addition, there was significant difference in change in SAPWD between the control and the CPAP groups.
we could not investigate the effect of CPAP treatment on SAPWD in patients with mild OSA. However, we found a significant correlation between reduction in SAPWD and log-transformed AHI in patients with moderate-to-severe OSA, suggesting that mild OSA patients may experience limited benefits with CPAP therapy on SAPWD. Further studies are needed to clarify the effects of CPAP therapy on SAPWD in patients with mild OSA. Finally, we did not obtain structural or functional information on the atrium in the present study; this information seems to be important for clarifying the mechanism of the relationship between OSA and delayed atrial conduction.
Conclusion
We found that OSA severity was significantly associated with prolonged SAPWD. In addition, CPAP therapy significantly shortened SAPWD in association with adherence to CPAP in patients with moderate-to-severe OSA. These findings suggest that OSA may cause an atrial conduction delay, possibly by atrial overload or left atrial remodeling by OSA-related pathophysiological effects, leading to an increased risk of AF development. However, this may be modifiable by alleviating OSA with CPAP therapy.
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